R ofecoxib (Vioxx), a selective COX-2 inhibitor, was approved for the treatment of osteoarthritis, acute pain, and menstrual pain in May 1999 and for use in rheumatoid arthritis in April 2002. Despite limited time on the market, this drug became a popular choice among a variety of prescribers.
The recent market removal of rofecoxib was based on a sequence of events. Instrumental in the decision was Merck's recent Adenomatous Polyp Prevention on Vioxx (APPROVe) trial, which enrolled 2,600 patients randomized to receive either Vioxx or placebo. In the first 18 months of this trial, both placebo-and Vioxx-treated patients had the same rate of cardiovascular events (0.375%). However, at 36 months, Vioxx-treated patients demonstrated twice as many cardiovascular events than placebo-treated patients (1.5% vs 0.75%). APPROVe was terminated early and Merck withdrew rofecoxib from the market on September 30, 2004.
Drug market removals due to adverse events are rare but not unusual (eg, cerivastatin, terfenadine). Typically, market withdrawals are due to adverse events not identified in premarketing clinical trials. Often the safety profile of a drug becomes more apparent as data are collected via postmarketing surveillance and programs that are in place to monitor adverse events.
Adverse drug event (ADE) surveillance and external reporting are essential components of drug safety efforts in the health care community and serve primarily as early warning signs for potential problems. A variety of voluntary and mandatory reporting and monitoring programs are available: Despite the breadth and scope of these programs, they did not detect the adverse cardiovascular events precipitating the Vioxx withdrawal. It took the long-term APPROVe trial to detect the excess risk of myocar-dial infarction or stroke associated with the drug. An event related to a commonly occurring disease is difficult to distinguish from an adverse event related to a drug.
It should be noted, however, that cardiovascular risk was a concern with rofecoxib prior to the results of the APPROVe trial. In February 2001, The FDA Arthritis Advisory Committee met to discuss the cardiovascular risk potentially associated with Vioxx. An independent analysis of these data from this meeting resulted in the recommendation that a trial be conducted addressing cardiovascular risk related to COX-2 inhibitors. 1 Theoretical evidence now also suggests that this may be a drug class effect. 2 This example highlights two important elements. The first is that the withdrawal of Vioxx will likely have an effect on postmarketing surveillance, not only for the COX-2 inhibitors, but for other agents as well. In addition, it illustrates the importance of adverse event reporting. Postmarketing surveillance, monitoring, and reporting remain integral to the health care community. Over the years, these efforts have resulted in changes in prescribing and drug withdrawals. Maintaining an active adverse event reporting and monitoring program in your facility optimizes medication safety for your patients.
